Coherus Biosciences logo Coherus Biosciences Inc (NASDAQ:CHRS) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $30.75.
CHRS has been the topic of a number of research analyst reports. ValuEngine upgraded Coherus Biosciences from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Cowen reiterated a “buy” rating and issued a $45.00 price objective on shares of Coherus Biosciences in a research note on Friday, November 2nd. HC Wainwright set a $28.00 price objective on Coherus Biosciences and gave the company a “buy” rating in a research note on Monday, November 5th. BidaskClub upgraded Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 10th. Finally, Zacks Investment Research raised shares of Coherus Biosciences from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Tuesday, October 30th.
Several institutional investors have recently added to or reduced their stakes in CHRS. Legal & General Group Plc increased its holdings in shares of Coherus Biosciences by 12.3% in the fourth quarter. Legal & General Group Plc now owns 9,095 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 998 shares during the period. Roman Butler Fullerton & Co. purchased a new position in Coherus Biosciences in the fourth quarter worth $122,000. State Board of Administration of Florida Retirement System grew its position in Coherus Biosciences by 16.5% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 22,095 shares of the biotechnology company’s stock worth $200,000 after acquiring an additional 3,122 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Coherus Biosciences in the third quarter worth $282,000. Finally, Boston Advisors LLC grew its position in Coherus Biosciences by 12.7% in the fourth quarter. Boston Advisors LLC now owns 33,060 shares of the biotechnology company’s stock worth $299,000 after acquiring an additional 3,725 shares in the last quarter. 96.74% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ CHRS opened at $14.74 on Monday. Coherus Biosciences has a twelve month low of $8.32 and a twelve month high of $20.66. The company has a market capitalization of $1.00 billion, a PE ratio of -3.29 and a beta of 3.66. The company has a current ratio of 5.31, a quick ratio of 5.31 and a debt-to-equity ratio of 8.29.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.
Read More: What is a Call Option?
Receive News & Ratings for Coherus Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Coherus Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at Coherus Biosciences Inc (CHRS) Given Average Recommendation of “Buy” by Brokerages